GSK will invest over $800 million to transform its Upper Merion, Pennsylvania site into a biopharmaceutical manufacturing and research hub, creating more than 300 jobs over five years. The investment will establish a combined drug manufacturing, research and development, quality testing, and digital operations center.
The investment signifies a significant expansion in biopharmaceutical manufacturing and research capacity in Pennsylvania, potentially boosting the regional economy through job creation and retention, and accelerating the development of new medicines.
GSK plans to invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating over 300 jobs within the next five years, according to an announcement from Pennsylvania Governor Josh Shapiro's office on Friday.
The investment will establish a comprehensive site in Montgomery County, integrating drug manufacturing, research and development, quality testing, and digital operations. GSK stated that construction is scheduled to commence in 2027, with the project supporting the production of biologic medicines for both clinical trials and commercial sale.
In addition to creating more than 300 new positions, the expansion is expected to retain approximately 4,500 existing full-time jobs in Pennsylvania. The facility will feature a new commercial-scale biologics manufacturing plant, a research pilot plant, and a centralized quality-control laboratory.
Pennsylvania officials indicated that GSK will qualify for state manufacturing tax incentives related to this investment. Combined with GSK's previously announced project in Lancaster County, the total planned investment in Pennsylvania amounts to nearly $1.7 billion, according to state officials. GSK, which has its U.S. headquarters in Philadelphia, stated the expansion aims to expedite the development and supply of future medicines.
Pick the topics you care about. Get only what matters, on your cadence.